

wherein R₁, R_{2a}, R_{2b}, R_{2c}, R₃, R₄ and n are as defined herein; and optionally thereafter converting one compound of the formula (I) into another compound of the formula (I).

5 In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein.

In another aspect, there is provided a compound as defined herein for use in therapy.

10 In another aspect, there is provided a compound as defined herein for use in the prophylaxis or treatment of cancer.

In another aspect, there is provided use of a compound as defined herein for the manufacture of a medicament for the prophylaxis or treatment of cancer.

15 WO2006/092430, WO2008/003702, WO01/68047, WO2005/007099, WO2004/098494, WO2009/141386, WO2004/030635, WO2008/141065, WO2011/026579, WO2011/028947, WO2007/003419, WO00/42026, WO2012/154760, WO2011/047129, WO2003/076416, WO2002/096873, WO2000/055153, EP548934, US4166117, WO2011/135376, WO2012/073017, WO2013/061074, WO2013/061081, WO2013/061077, WO2013/061080,
20 WO2013/179034, WO2013/179033, WO2014/174307 which each disclose a series of heterocyclyl derivatives.

DETAILED DESCRIPTION OF THE INVENTION

25 Unless the context indicates otherwise, references to formula (I) in all sections of this document (including the uses, methods and other aspects of the invention) include references to all other sub-formula (e.g. Ia, Ib, Ic, Id), sub-groups, preferences, embodiments and examples as defined herein.

wherein R_1 , R_{2a} , R_{2b} , R_{2c} , R_3 , R_4 and n are as defined in claim 1; and optionally thereafter converting one compound of the formula (I) into another compound of the formula (I).

5 21. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 19.

22. A compound as defined in any one of claims 1 to 19 for use in therapy.

10

23. A compound as defined in any one of claims 1 to 19 for use in the prophylaxis or treatment of cancer.

15

24. A compound for use in the treatment of cancer according to claim 23 wherein the cancer is bladder cancer, urothelial cancer, metastatic urothelial cancer, surgically unresectable urothelial cancer, breast cancer, glioblastoma, lung cancer, non small cell lung cancer, squamous cell lung cancer, adenocarcinoma of the lung, pulmonary adenocarcinoma, small cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, soft tissue sarcoma, head and neck squamous cell carcinoma, gastric cancer, oesophageal cancer, squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, cholangiocarcinoma, hepatocellular carcinoma.

20

25. A compound for use according to claim 24 wherein the cancer is urothelial cancer, metastatic urothelial cancer, or surgically unresectable urothelial cancer.

25

26. A compound for use according to claim 24 wherein the cancer is bladder cancer.

27. A compound for use according to claim 26 wherein the cancer is bladder cancer with a FGFR3 chromosomal translocation.

30


28. A compound for use according to claim 26 wherein the cancer is bladder cancer with a FGFR3 point mutation.

29. A compound for use in the treatment of cancer according to claim 23 wherein

- (i) the cancer is a tumour with a mutant of FGFR1, FGFR2, FGFR3 or FGFR4; or(ii)
the cancer is a tumour with a gain-of-function mutant of FGFR2 or FGFR3; or
(iii) the cancer is a tumour with over-expression of FGFR1.

5 30. A compound for use in the treatment of cancer according to claim 24 wherein the cancer is cholangiocarcinoma.


31. A compound for use in the treatment of cancer according to claim 23 wherein the



compound is


10

32. A compound for use in the treatment of cancer according to claim 24 wherein the




compound is

33. A compound for use in the treatment of cancer according to claim 25 wherein the




15 compound is

34. A compound for use in the treatment of cancer according to claim 26 wherein the




compound is

35. A compound for use in the treatment of cancer according to claim 27 wherein the




compound is

5 36. A compound for use in the treatment of cancer according to claim 28 wherein the



compound is


37. A compound for use in the treatment of cancer according to claim 29 wherein the



compound is

10

38. A compound for use in the treatment of cancer according to claim 30 wherein the



compound is

39. Use of a compound as defined in any one of claims 1 to 19 for the manufacture of a medicament for the prophylaxis or treatment of cancer.